ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Rapid testing with molecular syndromic panels of patients presenting at the emergency department with pneumonia at risk for multidrug-resistant pathogens.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- RESPIRE Score: Derivation and Validation of a New Risk Score for Prediction of Community-acquired Pneumonia Caused by Resistant Pathogens.Open forum infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPneumonia remains a major cause of morbidity and mortality worldwide. Rapid diagnostic testing with molecular syndromic panels (MSP) has proved useful for the management of antimicrobial treatment of hospital-acquired pneumonia (HAP). In this study, we evaluated the impact of early use of MSP testing in the Emergency Department (ED) for the management of antibiotic therapy in patients with moderate to severe CAP with risk factors for multi-drug-resistant pathogens (CAP-MDR). PATIENTS AND
methodsPatients presenting at the ED with diagnosis of moderate to severe CAP-MDR underwent microbiological analysis of lower respiratory tract specimens by culture and MSP testing (bioMérieux, FilmArray
resultsBetween June 2024 and May 2025, 93 patients were enrolled (age, 72.9 ± 13.9 years; 62.4% males). MSP testing identified one or more pathogens in 91.4% of cases. Modification of empiric antibiotic therapy, started according to local protocols, occurred in 65.6% of patients (escalation in 44.1% and de-escalation in 21.5% of cases) after 11.4 ± 6.3 h (IQR 12.0) since ED presentation.
conclusionsThe early use of MSP on lower respiratory samples collected in the ED from patients with diagnosis of moderate to severe CAP-MDR could allow a rapid and targeted modification of the empiric antibiotic therapy in these patients, with potential advantages on antimicrobial stewardship and patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.